Zoledronic acid (Reclast; Novartis) injection, approved earlier this year by the FDA for Paget's disease, has received a new indication for the treatment of postmenopausal osteoporosis. Reclast is the first once-yearly option available for this indication. It is administered as a single 15-minute infusion, unlike oral bisphosphonates, which must be taken daily, weekly, or monthly for the prevention or treatment of osteoporosis.
"The fact that Reclast is highly effective and can be administered once yearly represents a major milestone in the treatment of postmenopausal osteoporosis," said Felicia Cosman, MD, professor of clinical medicine at Columbia University. "For the first time we can ensure women receive a full year of the treatment they need to protect their bones."
The 3-year Pivotal Fracture Trial showed that zoledronic acid increased bone strength and reduced fractures in the hip, spine, and nonspine (eg, wrist, rib) regions.